USFDA inspection: Aurobindo Pharma receives 8 observations for Unit-XII
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2025-09-06 07:15 GMT | Update On 2025-09-06 07:16 GMT
Advertisement
Telangana: Aurobindo Pharma has announced that the company has received eight observations from the United States Food and Drug Administration (US FDA) for its Unit-XII, which includes both oral solids and injectable manufacturing unit, situated at Bachupally, Medchal Malkajgiri District, 500090, Telangana.
The facility was inspected from August 25 to September 05, 2025.
"At the end of the current inspection, a ‘Form 483’ was issued with a total of 8 observations for both (oral solids & injectable)," the company stated in a BSE filing.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.